| Document |
Document Title |
|
JP2009530324A |
The invention relates to NHE-3 inhibitor compounds of formula I: In which R1-R11 are more specifically defined herein. These substituted 2-amino-4-phenyl-dihydroquinolines are useful the treatment of various renal and respiratory disorde...
|
|
JP2009529374A |
A device for inhibiting adhesion of apposing human body tissue layers includes a scaffold having a designated mean pore size, relative density, and degradation half-life. The scaffold may be operably positioned between apposing tissue la...
|
|
JP2009528977A |
Methods and compositions for the treatment of fibrosing diseases are described. More specifically, the invention demonstrates that inhibiting or otherwise decreasing the activity of CCL21 either alone or in combination with CCL19 will be...
|
|
JP4306825B2 |
It is an object of the present invention to provide a pharmaceutical composition for effectively preventing or improving diseases having vascular dysfunction associated with insulin resistance. The present invention provides pharmaceutic...
|
|
JP2009527536A |
The invention relates to a method for removing a protein inhibitor from a liquid pharmaceutical preparation, said method comprising the steps of: (a) providing a sealed container comprising an initial liquid pharmaceutical preparation co...
|
|
JP4303196B2 |
The present invention relates to a gelatin derivative having an organic compound as a graft chain and a high-molecular weight micelle containing the gelatin derivative. As the organic compound, a low molecular weight compound such as suc...
|
|
JP2009161555A |
To provide a composition and a method, suitable for treating or preventing inflammatory diseases; to provide significant advantages compared with present procedures by treating problems accompanied with that of the present; and to furthe...
|
|
JP2009149668A |
To provide a method which reduces or prevents restenosis following invasiveness revascularization procedures, and to provide a composition therefor.The method for reducing or preventing the restenosis that occurs following the revascular...
|
|
JP4290555B2 |
This invention relates to compounds which are generally CRF-1 receptor antagonists and which are represented by Formula I or Formula II: wherein Ar is optionally substituted aryl or heteroaryl, R1-R4 are as defined in the specification; ...
|
|
JP4287050B2 |
A medicament is disclosed for reducing the risk of cross-healing ("adhesions") after surgery. The medicament is a dry powder comprising a surface active phospholipid which is capable of binding to mesothical membranes, and a spreading ag...
|
|
JP4289886B2 |
A wound closure system and methods utilizes a patient's own blood. The system preferably includes a chamber with a needle and a plunger for transferring and storing blood prior to surgery and the use of reversible anticoagulants. The cha...
|
|
JP2009125341A |
To provide an aesthetic plastic surgery injection container body appropriate for simple aesthetic plastic surgery using gel type prosthesis.The aesthetic plastic surgery injection container has gel type prosthesis containing polyacrylami...
|
|
JP4277022B2 |
The present invention provides a carbamoyl-type benzofuran derivative of the formula [1]: wherein Ring Z is a group of the formula: etc.; A is a single bond, and the like; Y is a cycloalkanediyl group, etc.; R 4 and R 5 are the same or d...
|
|
JP4276601B2 |
A method of preventing or reducing the incidence of post-operative adhesions in or associated with a body cavity, which comprises introducing into the body cavity a composition containing an aqueous solution or suspension or gel formulat...
|
|
JP4273407B2 |
A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP 4 agonist as an active ingredient. An EP 4 agonist, in which includes a compound p...
|
|
JP2009112314A |
To provide an improved vector so as to enable a targeted delivery system to be used in a clinical setting, and to provide a system for producing the improved vector.A method and a composition for producing a targeted delivery vector are ...
|
|
JP2009114153A |
To provide a tranilast-containing preparation as a gel-like suspension preparation or micronized suspension useful as a scarring inhibitor or vitreous body visualizer after operation and having effects equivalent to or higher than the ca...
|
|
JP2009102305A |
To provide a new isolated immunomodulatory polymer based on three-dimensional molecular structure determination of an immunomodulatory polymer, three-dimensional computer molecular modeling and rational drug design, and a method for desi...
|
|
JP4261049B2 |
Cyclosporine derivatives are disclosed which possess enhanced efficacy and reduced toxicity over naturally occurring and other presently known cyclosporins and cyclosporine derivatives. The cyclosporine derivatives of the present inventi...
|
|
JP4259614B2 |
The invention discloses a process and resuscitation solution for inducing repair of ischemically damaged organs and tissues, to the degree that impairment of function can be reversed; and preventing further tissue damage during restorati...
|
|
JP2009514818A |
The use of substituted amides for modulating the activity of 11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, ...
|
|
JP2009513521A |
Methods for treatment of IP antagonist mediated diseases or conditions by administration to a subject in need thereof a compound of formula (I) wherein R1, R2, A and X are as defined herein. Also disclosed are compounds and related compo...
|
|
JP4245192B2 |
PCT No. PCT/GB97/00069 Sec. 371 Date Sep. 4, 1998 Sec. 102(e) Date Sep. 4, 1998 PCT Filed Jan. 9, 1997 PCT Pub. No. WO97/25052 PCT Pub. Date Jul. 17, 1997The present invention relates to compositions for use in medicine, e.g. as infusion...
|
|
JP2009057428A |
To provide a low-toxicity water-absorbing polymer particle.This water-absorbing polymer particle is obtained by saponifying a copolymer obtained by copolymerizing a vinyl ester-based compound and an ethylene-based unsaturated carboxylic ...
|
|
JP2009051844A |
To provide compounds for treating wounds and/or fibrotic disorders.The compounds which influence the sex hormone system are used in treating wounds and/or fibrotic disorders. Preferred compounds for use in such treatments are steroid hor...
|
|
JP2009510048A |
Biodegradable carriers synthesized from ricinoleic acid oligoesters and aliphatic molecules having at least one carboxylic acid and at least one hydroxy or carboxylic acid group that are liquids or pastes at temperatures below 37° C. an...
|
|
JP4232866B2 |
A composition for inhibiting cell damage comprising FR901459 Substance as following formula (I) or its salt in admixture with pharmaceutically acceptable carriers or excipients.
|
|
JP4231657B2 |
To provide a capsule type medical treatment device which has a simple constituent free from electric wiring, is not enlarged in scale, and enables a remote operation for putting the capsule opening stopper on and out at a desired site or...
|
|
JP2009507848A |
Methods of protecting cells against cytotoxic insults are provided. The methods involve administering a composition including a CpG oligonucleotide to a subject. The methods are applicable to the protection of neural and non-neural cells...
|
|
JP2009507890A |
The present invention relates to the use of a compound of formula (I), wherein R1 is pyridyl or thiazolyl, any of which may optionally be substituted with C1-8alkyl or C2-8alkenyl; and a) R2 is methoxy and n is zero or one; or b) R2 is c...
|
|
JP4230767B2 |
The present invention relates to water-insoluble, crosslinked amide derivatives of hyaluronic acid and manufacturing method thereof, where the amide derivatives of hyaluronic acid are characterized by crosslinking, of polymer or oligomer...
|
|
JP2009507081A |
The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on an HDac inhib...
|
|
JP4222614B2 |
It is intended to provide a psychogenic pain therapeutic agent that exerts an excellent therapeutic effect on psychogenic pain which is an intractable disease. More specifically, it is intended to provide a psychogenic pain therapeutic a...
|
|
JP4221368B2 |
Template-fixed β-hairpin peptidomimetics of the general formula (I) wherein Z is a template-fixed chain of 12 α-amino acid residues which, depend on their positions in the chain (counted starting from the N-terminal amino acid) are Gly...
|
|
JP4221383B2 |
It is intended to provide a remedy for neurogenic pain exerting an excellent therapeutic effect on neurogenic pain which is an intractable disease. More specifically speaking, it is intended to provide a remedy for neurogenic pain which ...
|
|
JP2009024022A |
To provide a method for perioperatively inhibiting pain and inflammation or spasm, or pain, inflammation and spasm at wounds.In this method, a dilute solution in a physiologic liquid carrier including a plurality of inhibitors selected f...
|
|
JP2009504643A |
A kit of lyophilized thrombin and lyophilized fibrinogen comprises fibrinogen of 50-100 mg/ml, thrombin of 100-1000 IU/ml and 20-60 mmol/L CaCl2 used to compound fibrin membrane. The lyophilized thrombin and lyophilized fibrinogen are ap...
|
|
JP2009022759A |
To provide devices and methods for preventing formation of scar tissues and/or adhesion subsequent to surgical treatment, an injury, or a wound.The invention includes various devices and methods, in which antiproliferative chemical havin...
|
|
JP4217843B2 |
To provide a method for extracting fibrin paste in a short time and a freeze-defrosting device. A fibrin paste is recovered by feeding whole blood from a whole blood receiving part 101 to a filtering part 102, leaving a blood cell part i...
|
|
JP2009503117A |
Provided herein are novel sirtuin-modulating compounds (XII) and (XIII). The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders includin...
|
|
JP4216071B2 |
Novel urea and urethane derivatives of general formula (I) in which R1, R2, R3, R5, R5', X, Y, B, m, n and o are as defined in Patent Claim 1 , and physiologically acceptable salts or solvates thereof are integrin inhibitors and can be e...
|
|
JP4217037B2 |
|
|
JP2009007371A |
To modify GLP-1, Exendin3, Exendin4 and other insulinotropic peptides to impart long lasting activity in vivo while keeping their low toxity and merits in treatment.A modified insulinotropic peptides consists of an Exendin-4(1-39)-Lys40(...
|
|
JP4208967B2 |
PCT No. PCT/EP97/05485 Sec. 371 Date Jun. 9, 1999 Sec. 102(e) Date Jun. 9, 1999 PCT Filed Oct. 7, 1997 PCT Pub. No. WO98/16213 PCT Pub. Date Apr. 23, 1998Methods of facilitating detaching pathological tissues from healthy tissues with wh...
|
|
JP2009001574A |
To provide a composition useful for long-lasting pain-relief from mucosal damages such as mucosal inflammations, abrasions, ulcerations, lesions, traumas and incisions, without significant systemic absorption.The composition comprises a ...
|
|
JP2009500457A |
The present invention provides methods of treating, preventing or ameliorating the symptoms of T cell-mediated immunological diseases, particularly autoimmune diseases, through the use of anti-CD3 antibodies. In particular, the methods o...
|
|
JP4201818B2 |
Selective androgen receptor modulator (SARM) compounds having the formula (II): wherein Z XisO; is NO 2 , CN, COR, or CONHR; Y is I, CF 3 , CH 3 , H, Br, Cl, F or Sn(R) 3 ; R is an alkyl, aryl, phenyl, alkenyl, haloalkyl, haloalkenyl, ha...
|
|
JP2008302235A |
To provide a new biomaterial for the field of surgery (concretely, for preventing post-surgical adhesion).The biomaterial essentially comprises esterified derivatives of hyaluronic acid or cross-linked derivatives of hyaluronic acid.
|
|
JP4198988B2 |
Methods and compositions for the treatment of ocular neovascularization (CNV) and macular degeneration. The invention includes combining laser treatment with administration of a neuroprotectant.
|
|
JP2008297321A |
To provide a low molecular-weight caspase inhibitor that is powerful, stable and film-permeable in order to effectively inhibit in vivo apoptosis.This invention is in the field of pharmaceutical chemistry and relates to a new compound in...
|
